Type | Administration error/deviation | Interim recommendation |
Site/route |
|
|
|
| |
Age |
|
|
|
| |
Product and dosage |
|
|
|
| |
Storage and handling |
|
|
|
| |
Intervals |
|
|
|
| |
Interchangeability |
|
|
Diluent (Pfizer-BioNTech COVID-19 Vaccine formulation only [orange cap and maroon cap]) |
|
|
|
| |
|
| |
|
| |
|
| |
|
| |
Diluent (Pfizer-BioNTech COVID-19 formulation that should not be mixed with diluent, ie, gray cap) |
|
|
CDC: United States Centers for Disease Control and Prevention; VAERS: Vaccine Adverse Event Reporting System; FDA: US Food and Drug Administration; EUA: emergency use authorization.
* Do not administer the second dose until the person becomes eligible to receive vaccination (either by reaching the authorized age or if the authorization is extended to include additional age groups), even if this results in the second dose being administered after the recommended interval between doses. In addition to the minimum age, some experts suggest delaying the second dose for 8 weeks after the invalid dose based on the potential for increased reactogenicity and the rare risk of myocarditis and pericarditis from mRNA COVID-19 vaccine.
¶ If the administration error resulted in a higher-than-authorized vaccine dose, in general a subsequent dose may still be administered at the recommended interval. However, if local or systemic side effects following vaccination are clinically concerning (outside of the expected side effect profile), lead to serious adverse reactions, or are ongoing at the time of the subsequent dose, this dose might be delayed, but this decision should be assessed on a case-by-case basis.
Δ FDA authorization allows for dosing options for certain situations where a child ages from a younger to older age group; see Transitioning from a younger to older age group. If the dosing is in accordance with the FDA EUA, it is not considered an error and VAERS reporting is not indicated.
◊ Some experts suggest delaying the repeat dose for 8 weeks after the invalid dose based on the potential for increased reactogenicity and the rare risk of myocarditis and pericarditis from mRNA (Moderna or Pfizer-BioNTech) and Novavax COVID-19 vaccines, particularly in groups at increased risk for myocarditis and pericarditis (eg, males ages 12 to 39 years). Individual risk for COVID-19 and the likelihood for an adverse event following vaccination should be taken into consideration when recommending a longer interval. It is acceptable to administer the repeat dose at an interval earlier than 8 weeks if the interval is not sooner than the minimal interval noted in this table.
§ As of the date of this update, current manufacturer contact information is:Please see the package inserts and EUA provider factsheets for the most up-to-date manufacturer information.
¥ Vaccine doses administered up to 4 days before the minimum interval may be counted and do not need to be repeated.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟